Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine types.

Martin RyserValérie Berlaimont Naveen KarkadaAttila MihalyiRino RappuoliRobbert van der Most

Published in: Expert review of vaccines (2019)

Heterogenous overall efficacy against CIN3 between AS04-HPV and qHPV is driven by differential efficacy against lesions that do not contain vaccine types, which may be related to the impact of different adjuvants on the immune response.

Keyphrases

phase iii
immune response
open label
clinical trial
high grade
phase ii
toll like receptor